Web Analytics


J A P A N   T E C H N O L O G Y   G R O U P    N E E D S    L I S T I N G




Novel strategies to selectively target adipose tissue


Boehringer Ingelheim



Wellspring Announces Japan Technology Group as a Channel Partner for Japan Market

Wellspring Worldwide, the leader in software for technology transfer and corporate innovation management, today appointed Japan Technology Group (JTG) as a strategic channel partner in Japan.
Click to see full details...

Contract to research and identify European industrial technologies of high cooperation and business potential for Japan.

Japan Technology Group as member of the International Consortium has been awarded a contract to research and identify European industrial technologies of high cooperation and business potential for Japan. Click to see full details...


TECHNOLOGY VENTURING SERVICES, S.L.U ( everis Group, subsidiary of the NTT Data Group)

What people are saying
about JTG

“JTG has proven to be very dependable and as advertised, they are extremely well connected to the research community in Japan.  Their core expertise and approach to doing business are in alignment with our objectives.  As a result, we have been able to establish several strategic relationships and collaboration opportunities.”

University of Hawai‘i
Larry Cutshaw
Director Business Development, Office of the Vice President for Research and Innovation


Respond, Apply or Request more info

What is the context of the problem that we would like to solve?

Based on estimations by the World Health Organization, approximately 300 million people

will be obese in 2035. With this, obesity presents a major health concern with increasing

prevalence worldwide.

Therapies aiming at regulating food intake currently present the most effective medical

treatment for obesity. However, as reduction of food intake is usually accompanied by

reduced energy expenditure, efficacy of such approaches and in particular the potential for

sustained weight loss is limited. Therefore, combinations with energy expenditure

increasing mechanisms are urgently needed.

Exploiting the full therapeutic potential of energy expenditure mechanisms needs to

incorporate adipose tissue specific mechanisms, as it presents a major tissue regulating

energy metabolism. Pharmacological utilization of therapeutic targets within adipose tissue

ultimately depends on tissue-selective drug delivery. Whereas progress was made in the

past targeting liver via N-acetylgalactosamine (GalNAc)-conjugates and tissue specific cell

surface receptor, no suitable surface proteins were identified that exclusively express in

adipocytes. Based on the urgent need to incorporate energy expenditure mechanisms in

the treatment of obesity, there is a high interest in identifying and characterizing novel

approaches for a cell-type specific targeting of adipose tissue.

What potential solutions could be in scope?

Any unconventional but feasible approach that allows identifying and verifying adipose

tissue-specific molecules for drug-delivery approaches, from biological matrices such as

primary cells, cell lines, organoids, or tissues. Different adipose depots, e.g. white and

brown adipose tissue, are considered equally relevant. The species is not only limited to

humans, however, proposals demonstrating feasibility in human systems are prioritized.

In addition, any already identified adipose-specific molecule or technical approach to

specifically target adipose tissue, not yet public or described in the context of obesity is of

interest, provided that there is a translatability to humans or at least evidence in metabolic

relevant cellular or animal models.

The proposal needs to be highly feasible, should be based on established and existing

methods, assays and involve tools or reagents that are either available or which can be

easily produced. We expect that the project will be executed in your laboratory and takes

advantage of existing technologies and assays.

What potential solutions would be out of scope?

Please note that any proposal ultimately inhibiting adipogenesis or ablating adipose tissue

will not be considered.

Projects that are based on technologies that require first substantial establishment and

validation (no previous hands-on experience) will be deprioritized.

What benefits do we offer to you in exchange for having submitted a solution?

We are open to all proposals that can fully or partially meet its requirements.

If your project is selected, you will have the opportunity to directly collaborate with the

Cardio Metabolic Diseases Research team of Boehringer Ingelheim. You can expect

appropriate funding for the prospective collaboration period. The exact funding request

should be outlined in your proposal. As a framework, we suggest that your initial funding

request is structured in milestones and does not exceed 200,000 euros per submitted

project in total.

The opportunity for a funded stay at Boehringer Ingelheim for technology exchange /

training is potentially available, as is the availability of custom biological tools and


Our collaboration agreement will provide full transparency about each partner’s rights &

obligations (including intellectual property rights). As part of the agreement you will be

encouraged to publish following the collaboration agreement (to be negotiated in good


To maintain the highest degree possible in an open innovation environment, we plan to

announce the winner(s) publicly and feature them on opnMe.com and our social media

channels. We would guide you through this process and as part of it we would kindly ask

for your upfront consent, in case our scientific jury had selected your answer.

What are the key success criteria on which we base our selection for the best answer?

We are seeking research collaboration proposals that contain:

• A well-structured proposal outlining a new and compelling scientific approach.

• Outlining of the technical feasibility, and potentially existing data or previous publications that

support feasibility / experience with outlined technology, based on existing techniques and

established assays.

• Your exact funding request should be outlined in your proposal based on a well-thoughtthrough

project. The project should be structured in milestones and planned with key decision

points (clear Go/No-Go criteria). The funding request for the initial milestones resulting in a

Go/No-Go decision should not exceed 200,000 euros per submitted project in total.

• Proven track record in the required field of expertise.

• Ability to implement the outlined solution as part of a scientific collaboration project with

Boehringer Ingelheim including access to a laboratory.


We are currently seeking answers for the following scientific challenge: How would you

propose to identify and verify novel approaches to specifically target adipose tissue for

delivery of anti-obesity therapeutics?

All incoming answers accompanied by a collaboration proposal will be evaluated by a

scientific jury, and, upon selection, chosen proposals are pursued through a joint

collaboration with the successful applicants. Initial funding of up to 200,000 euros will be

available for each selected proposal.





or E-mail us at info@japantechnologygroup.com. 
Please specify which technology need(s) you are responding to.

No cost for submitting a proposal

Benefits of responding through JTG

  •  Support and facilitate direct communication with the technology seekers
  •  Assist and guide preparing a effective proposal and materials
  •  Consult strategic planning for negotiations for licensing or collaboration
  •  Act as your representative though out process to conclusions
  •  Provide necessary legal advices and supports based on your needs
Questions and inquiries concerning our services

Tel: +81-3-6825-1418

E-mail: info@japantechnologygroup.com